The Effect of Synaquell™ in Contact Sport Athletes

Sponsor
Mayo Clinic (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06104670
Collaborator
Sanford Health (Other)
40
1
4
25
1.6

Study Details

Study Description

Brief Summary

This research is being done to investigate the dietary supplement, Synaquell (TM), for effects on brain function in youth contact sport athletes.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Synaquell(TM)
  • Dietary Supplement: Placebo
N/A

Detailed Description

This randomized clinical trial will compare a brain health supplement (Synaquell) with placebo in both male and female ice hockey players over the course of an entire season. The repeated measure design will compare pre- and post-season objective brain health parameters, including quantitated EEG (Neurocatch), blood & saliva biomarkers, impact monitoring mouthguard, and a rapid number naming test (King Devick).

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Masking Description:
The study staff responsible for distributing SynaquellTM will not be blinded to the intervention, but all subjects and other study staff will be blinded.
Primary Purpose:
Supportive Care
Official Title:
The Effect of Synaquell™ on Objective Measures of Brain Health in Male and Female Youth Contact Sport Athletes
Anticipated Study Start Date :
Nov 1, 2023
Anticipated Primary Completion Date :
Mar 1, 2025
Anticipated Study Completion Date :
Dec 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Experimental: Synaquell Male Group

Male youth hockey players will receive the dietary supplement Synaquell, twice-daily during the hockey season. Due to difference in game rules and playing styles, males and females will be treated as two separate arms of the research protocol.

Dietary Supplement: Synaquell(TM)
7.9 grams (1 scoop) of Synaquell powder mixed with 12 ounces of water two times per day for the duration of the sport season. The daily amount taken by each participant is (15.8 grams).

Placebo Comparator: Placebo Comparator: Placebo Male Group

Male youth hockey players will receive the placebo twice-daily, during the hockey season. Due to difference in game rules and playing styles, males and females will be treated as two separate arms of the research protocol.

Dietary Supplement: Placebo
7.9 grams (1 scoop) of placebo powder mixed with 12 ounces of water two times per day for the duration of the sport season. The daily amount taken by each participant is (15.8 grams). The placebo looks, smells, and tastes like Synaquell but does not contain active ingredient.

Experimental: Experimental: Synaquell Female Group

Female youth hockey players will receive the dietary supplement Synaquell, twice-daily during the hockey season. Due to difference in game rules and playing styles, males and females will be treated as two separate arms of the research protocol.

Dietary Supplement: Synaquell(TM)
7.9 grams (1 scoop) of Synaquell powder mixed with 12 ounces of water two times per day for the duration of the sport season. The daily amount taken by each participant is (15.8 grams).

Placebo Comparator: Placebo Comparator: Placebo Female Group

Female youth hockey players will receive the placebo twice-daily, during the hockey season. Due to difference in game rules and playing styles, males and females will be treated as two separate arms of the research protocol.

Dietary Supplement: Placebo
7.9 grams (1 scoop) of placebo powder mixed with 12 ounces of water two times per day for the duration of the sport season. The daily amount taken by each participant is (15.8 grams). The placebo looks, smells, and tastes like Synaquell but does not contain active ingredient.

Outcome Measures

Primary Outcome Measures

  1. Change in N100 Amplitude [Baseline, Postseason (approximately 6 months).]

    Obtained by EEG recording of N100 potential amplitude. This measures is subsequently linearly transformed to a standardized score on a 0-100 scale, with larger peak amplitudes and shorter peak latencies resulting in higher scores. Changes in brain vital sign scores are depicted within a radar plot format, with the transformation process preserving the essential ERP results but enabling practical, simplified interpretation.

  2. Change in N100 Latency [Baseline, Postseason (approximately 6 months).]

    Obtained by EEG recording of N100 potential latency. Increased latencies are indicative of slower responses. Obtained by EEG recording of N100 potential amplitude. This measures is subsequently linearly transformed to a standardized score on a 0-100 scale, with larger peak amplitudes and shorter peak latencies resulting in higher scores. Changes in brain vital sign scores are depicted within a radar plot format, with the transformation process preserving the essential ERP results but enabling practical, simplified interpretation.

  3. Change in P300 Amplitude [Baseline, Postseason (approximately 6 months).]

    Obtained by EEG recording of P300 potential amplitude. Increased amplitudes are indicative of larger signals. This measures is subsequently linearly transformed to a standardized score on a 0-100 scale, with larger peak amplitudes and shorter peak latencies resulting in higher scores. Changes in brain vital sign scores are depicted within a radar plot format, with the transformation process preserving the essential ERP results but enabling practical, simplified interpretation.

  4. Change in P300 Latency [Baseline, Postseason (approximately 6 months).]

    Obtained by EEG recording of P300 potential latency. Increased latencies are indicative of slower responses. This measures is subsequently linearly transformed to a standardized score on a 0-100 scale, with larger peak amplitudes and shorter peak latencies resulting in higher scores. Changes in brain vital sign scores are depicted within a radar plot format, with the transformation process preserving the essential ERP results but enabling practical, simplified interpretation.

  5. Change in N400 Amplitude [Baseline, Postseason (approximately 6 months).]

    Obtained by EEG recording of N400 potential amplitude. Increased amplitudes are indicative of larger signals.This measures is subsequently linearly transformed to a standardized score on a 0-100 scale, with larger peak amplitudes and shorter peak latencies resulting in higher scores. Changes in brain vital sign scores are depicted within a radar plot format, with the transformation process preserving the essential ERP results but enabling practical, simplified interpretation.

  6. Change in N400 Latency [Baseline, Postseason (approximately 6 months).]

    Obtained by EEG recording of N400 potential latency. Increased latencies are indicative of slower responses.This measures is subsequently linearly transformed to a standardized score on a 0-100 scale, with larger peak amplitudes and shorter peak latencies resulting in higher scores. Changes in brain vital sign scores are depicted within a radar plot format, with the transformation process preserving the essential ERP results but enabling practical, simplified interpretation.

  7. Change in blood biomarker: NfL [Baseline, postseason (approximately 6 months).]

    Blood will be at a biomarker level. We will investigate the biomarker neurofilament light (NfL). BDNF. The biomarker will be measured in Nanograms per Milliliter (ng/ml).

  8. Change in blood biomarker SNCB. [Baseline, postseason (approximately 6 months).]

    Blood will be at a biomarker level and B-Synuclein will be investigated. The biomarker will be measured in Nanograms per Milliliter (ng/ml).

  9. Change in blood biomarker vWF. [Baseline, postseason (approximately 6 months).]

    Blood will be at a biomarker level and Von Willebrand Factor (vWF) will be investigated. The biomarker will be measured in Nanograms per Milliliter (ng/ml).

  10. Change in blood biomarker SNCA. [Baseline, postseason (approximately 6 months).]

    Blood will be at a biomarker level and A-Synuclein (SNCA) will be investigated. The biomarker will be measured in Nanograms per Milliliter (ng/ml).

  11. Change in blood biomarker BDNF. [Baseline, postseason (approximately 6 months).]

    Blood will be at a biomarker level and Brain Derived Neurotrophic Factor (BDNF) will be investigated. The biomarker will be measured in Nanograms per Milliliter (ng/ml).

Secondary Outcome Measures

  1. Change in King-Devick Test (KDT) scored [Baseline, postseason (approximately 6 months).]

    A rapid number-naming test that requires individuals to read 3 numbered patters aloud as fast as possible, the resulting time if the KDT score. The post-season score is compared to the pre-season baseline. An increase in the number of seconds required to read the 3 number patterns is considered to be significant.

  2. Impact Monitor Mouthguard Acceleration [Beginning of practice to last game (approximately 6 months).]

    The Impact monitor mouthguard measures head acceleration.

  3. Impact Monitor Mouthguard Rotation [Beginning of practice to last game (approximately 6 months).]

    The Impact monitor mouthguard measures rotation of the head.

  4. Impact Monitor Mouthguard Head Impacts [Beginning of practice to last game (approximately 6 months).]

    The Impact monitor mouthguard measures the number of head impacts.

Eligibility Criteria

Criteria

Ages Eligible for Study:
13 Years to 19 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Fluent English Speakers

  • Medically cleared to play contact sport

Exclusion Criteria:
  • An allergy to the ingredients of Synaquell™ or the placebo (ingredients listed on page

  • Clinically documented hearing issues,

  • In-ear hearing aid or cochlear implant

  • Implanted pacemaker or defibrillator

  • Metal or plastic implants in skull

  • Lack of verbal fluency in the English language

  • History of seizures

  • Allergy to rubbing alcohol or EEG gel

  • Pregnancy

Contacts and Locations

Locations

Site City State Country Postal Code
1 Mayo Clinic in Rochester Rochester Minnesota United States 55905

Sponsors and Collaborators

  • Mayo Clinic
  • Sanford Health

Investigators

  • Principal Investigator: Michael Stuart, MD, Mayo Clinic

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
Michael J. Stuart MD, Principal Investigator, Mayo Clinic
ClinicalTrials.gov Identifier:
NCT06104670
Other Study ID Numbers:
  • 23-005242
First Posted:
Oct 27, 2023
Last Update Posted:
Oct 27, 2023
Last Verified:
Oct 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Michael J. Stuart MD, Principal Investigator, Mayo Clinic

Study Results

No Results Posted as of Oct 27, 2023